Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. - Wikidata - awgldk - TriplyDB

Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.

Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.

http://www.wikidata.org/entity/Q30427104

about

Mineral and bone disorder after kidney transplantation Vascular calcification, bone and mineral metabolism after kidney transplantation FGF23 in Acute and Chronic Illness Fibroblast growth factor 23 Bone disease in pediatric chronic kidney disease FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease.Management of mineral and bone disorder after kidney transplantation.Association of pretransplant serum phosphorus with posttransplant outcomes.FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts.The use of fibroblast growth factor 23 testing in patients with kidney disease.Effect of niacin on FGF23 concentration in chronic kidney disease.FGF23 protein expression in coronary arteries is associated with impaired kidney function.Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study.Chronic kidney disease: mineral and bone disorder in children.A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model.Plasma fibroblast growth factor 23 concentration is increased and predicts mortality in patients on the liver-transplant waiting list.Fibroblast growth factor 23 and incident CKD in type 2 diabetes.Circulating fibroblast growth factor 23 is associated with angiographic severity and extent of coronary artery disease.Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease.Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients.Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD.Fibroblast growth factor 23 in patients undergoing peritoneal dialysis Mineral metabolism in European children living with a renal transplant: a European society for paediatric nephrology/european renal association-European dialysis and transplant association registry study Fibroblast growth factor 23 and acute kidney injury.Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women.Renal phosphate loss in long-term kidney transplantation FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).Long term evolution of endothelial function during kidney transplantation.Update on fibroblast growth factor 23 in chronic kidney disease.Phosphocalcic Markers and Calcification Propensity for Assessment of Interstitial Fibrosis and Vascular Lesions in Kidney Allograft Recipients.Npt2b deletion attenuates hyperphosphatemia associated with CKD.A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation.Pathophysiology of the chronic kidney disease-mineral bone disorder.Fibroblast growth factor 23 and bone mineralisation.Fibroblast growth factor-23 and chronic allograft injury in pediatric renal transplant recipients: a Midwest Pediatric Nephrology Consortium study.Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.

P2860

Q26771398-3AEF259D-52A3-4EEA-B336-4DAADAF1F60F Q26771400-4934D867-7DE9-400F-995C-4007BE2EB670 Q26778554-DBBEF920-2335-4CD5-A5AC-33AECCFCCA56 Q26829294-15E1AC6D-3B6D-4EFC-A2B3-7654FCF7456B Q26864102-351F8A76-D9FD-41F6-A99F-41DCF5C05408 Q27687769-39799A73-C079-4B77-8CCD-387EC21B7FE4 Q30418461-0B959C95-5255-42E1-BECE-34A2FA883E47 Q30424192-9968767D-C7A0-4A9F-9715-24A2ACDF3463 Q33793927-743AB63E-31DB-45B5-86BE-3214F6DE1393 Q33835743-44D9A24C-F7C7-41CA-9FD8-BA79FABC3521 Q33914268-85CF5632-58C0-46CE-A9EE-28B5E8094AE1 Q33985430-A07FE090-779E-4AF3-819E-568FE9B158C8 Q34027316-4D43551D-F63C-423D-93B8-724D97A88A9F Q34059805-AFBB4095-A36B-4CFE-BA1B-22092306FC81 Q34402661-0B1DCD8D-6E9F-45A9-A6DF-D3866D996847 Q34412241-194273D8-49A9-4745-9C98-724CCAAFD0FD Q34794004-3BD1A3E7-157E-4396-A811-98977AABA15E Q34828731-38F4602A-E831-4D36-B101-67326F8145B6 Q34981550-D7EF0329-98ED-46AC-B90B-3DBE301B8904 Q35067500-05AA589E-4F2D-4434-9C5B-6CE6B5CB24D2 Q35124858-54408195-A9E3-49F4-9257-3E8516EAA744 Q35207839-C78EA2D5-4568-48A0-AC54-C4B9ABF3DBF7 Q35228536-8045E5C6-53BF-4FCF-9FE2-81B2DE344E30 Q35499669-666E44BF-221E-4206-9374-1EF61A41251B Q35576091-CFCF03F6-B2C8-4DB7-86A1-CE450D28DDB3 Q35690579-D7EA439A-4456-4292-ACA1-67D12A6ADBA3 Q35692453-DD7A06B7-5147-4F5D-9AC7-483B1D259C05 Q35758546-17F4A8EA-B311-427D-A977-9113C60B2376 Q35917428-44747000-6B93-49E0-AA6E-4A542FF95D58 Q35965337-5E1F6AB6-F1B1-4D98-83EC-F80146F8025A Q36095111-0A522986-8CAB-4117-A560-48800B183A25 Q36172106-1BE2F290-9E1F-4287-8042-4EF6A2F82261 Q36210285-D7046B52-2079-420B-93EC-C477223C00ED Q36236289-27B12A74-10BC-43F8-A023-F251A0C7701B Q36280326-5E882764-822A-4F00-9166-DA9230365D1D Q36381365-5048F492-902C-4DF2-AE10-4BA283821F46 Q36425115-75741D83-AA15-4A7B-8AF1-C2D6EA792D2F Q36756061-C26DF8CA-55ED-4CF8-ADF5-B73E848559FD Q36759150-E838A640-E74B-4B6C-9D08-C0C99FDEC149 Q36810501-FE128916-657F-4D6E-B327-CC0F344AD3B2

P2860

Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.

http://www.wikidata.org/entity/Q30427104

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Elevated fibroblast growth fac ...... transplant loss and mortality.

@ast

Elevated fibroblast growth fac ...... transplant loss and mortality.

@en

type

label

Elevated fibroblast growth fac ...... transplant loss and mortality.

@ast

Elevated fibroblast growth fac ...... transplant loss and mortality.

@en

prefLabel

Elevated fibroblast growth fac ...... transplant loss and mortality.

@ast

Elevated fibroblast growth fac ...... transplant loss and mortality.

@en

P1433

Q30427104-407B3D22-22D7-4A8C-B591-65B0AA4BC57B

P1476

Q30427104-6C561DD6-E5CE-480E-9F15-D34FAC660CB4

P2093

Q30427104-14DF458A-F074-4458-82A1-EA40816C4D8E

Q30427104-5C06F255-AF8C-4CAA-9450-55A6D5AEA894

Q30427104-7F840C3E-53B0-4326-B7BD-7D768737ED5E

Q30427104-80C26771-4415-4518-B254-1BA706AAF6B3

Q30427104-8E763C78-B03F-45C2-A0A0-E5166ACE1422

Q30427104-92E5CF4B-81DD-482A-8506-0277C171356B

Q30427104-A4DBF4AF-C375-43FA-95C4-28D3251B2EAD

Q30427104-B99E8145-878D-4536-AA50-360430F49286

Q30427104-C4CA0966-23B1-40E4-A934-A79C674A5A8E

Q30427104-D2EB2EC7-A933-426E-AA30-A24B690D73E5

P2860

Q30427104-09479FA8-9FE6-474F-A053-477D1075B53B

Q30427104-0B560CAF-741B-4C89-9FB1-75718FDFE48D

Q30427104-21BC7D3A-B79D-4FB8-A6CD-5702CE545D94

Q30427104-31B9CB1D-32F3-4234-B3E9-B3485A65D1E6

Q30427104-36C81D97-A11E-489B-8F46-31EAA97E9842

Q30427104-384FA7A8-6B0A-4EA4-AD6F-C87CC2E29332

Q30427104-42005875-BD0B-45D4-90FD-AB07875FE7F4

Q30427104-476A43AC-5783-4D18-A61B-E69B6D3883CF

Q30427104-4B540E05-A4D2-410F-8E29-E854EF63D7B3

Q30427104-4CA058A8-4786-4F7B-961B-485766A96E2D

P304

Q30427104-BC10426A-8715-45B5-82DB-5DC333BA41E3

P31

Q30427104-6B88BE75-6A09-44ED-A3FA-EC6F7EE60E0A

P356

Q30427104-F6858645-B6B7-4C1E-AE40-A4F9C166F883

P433

Q30427104-C964F9AC-1709-427D-B7AB-C3C96057AE18

P478

Q30427104-8CA785BD-9AE2-4CC6-A3C9-5F11B889B07B

P50

Q30427104-29CDC873-A741-42D3-A447-7338752E0362

Q30427104-E528980C-2CE0-4E2A-B90D-2492682F49E3

P577

Q30427104-5190D71C-103B-41D9-899F-DA88F080DF0D

P5875

Q30427104-6A646C62-7C71-4227-97B6-6FB7901705A1

P698

Q30427104-8EEB8BA4-1416-41F6-950C-1E663154803C

P921

Q30427104-D76A7610-B7FD-47F2-8CA9-00681072148C

P932

Q30427104-A20E6328-387C-4EB5-AA28-A861703004F0

P356

P1433

Journal of the American Society of Nephrology

P1476

Elevated fibroblast growth fac ...... transplant loss and mortality.

@en

P2093

Akos Ujszaszi

http://www.w3.org/2001/XMLSchema#string

Anna Rudas

http://www.w3.org/2001/XMLSchema#string

Ansel P Amaral

http://www.w3.org/2001/XMLSchema#string

Istvan Kiss

http://www.w3.org/2001/XMLSchema#string

Istvan Mucsi

http://www.w3.org/2001/XMLSchema#string

Janos Kosa

http://www.w3.org/2001/XMLSchema#string

Laszlo Rosivall

http://www.w3.org/2001/XMLSchema#string

Maria E Czira

http://www.w3.org/2001/XMLSchema#string

Myles Wolf

http://www.w3.org/2001/XMLSchema#string

Peter Lakatos

http://www.w3.org/2001/XMLSchema#string

P2860

Vitamin D deficiency

Klotho converts canonical FGF receptor into a specific receptor for FGF23

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

Inhibition of acute and chronic allograft rejection in mouse models by BXL-628, a nonhypercalcemic vitamin D receptor agonist.

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

P304

956-966

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2010080894

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Miklos Z Molnar

Csaba P. Kovesdy

P577

2011-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50850685

http://www.w3.org/2001/XMLSchema#string

P698

21436289

http://www.w3.org/2001/XMLSchema#string

P921

P932

3083317

http://www.w3.org/2001/XMLSchema#string